title: [Outcomes of high-risk prostate cancer patients at Hakodate Goryoukaku Hospital].
abstract: We assessed the outcomes of high-risk prostate cancer patients who received radical prostatectomy (RP), external beamradiation therapy (EBRT) or androgen deprivation therapy (ADT). Two hundred nineteen patients who were diagnosed with pathologically confirmed high-risk prostate cancer as defined by D'Amico between 2005 and 2011 were included in this study. Of them, 74 patients underwent RP. The 5-year cancer-specific survival (5yCSS) and 5-year PSA recurrence-free survival (5yPRFS) rates were 100 and 67.2%, respectively. A positive surgical margin and Gleason score≧8 were risk factors for PSA recurrence. The 5yPRFSs were 100, 74.4% and 'unmeasurable' for patients with 0, 1 and 2 risk factors, respectively. Ninety patients underwent EBRT. The 5yCSS and 5yPRFS rates were 95.2 and 74.2%, respectively. Fifty-five patients underwent ADT alone. Their 5yCSS and 5yPRFS rates were 93. 3 and 64. 3%, respectively. There was no significant difference in 5yCSS and 5yPRFS rates among the treatment groups. These results show that RP can be a treatment option for high-risk prostate cancer patients.
authors.affiliation: The Department of Urology, Hakodate Goryoukaku Hospital.
authors.forename: Kosuke
authors.initials: K
authors.lastname: Shibamori
authors.affiliation: The Department of Urology, Hakodate Goryoukaku Hospital.
authors.forename: Fumimasa
authors.initials: F
authors.lastname: Fukuta
authors.affiliation: The Department of Urology, Hakodate Goryoukaku Hospital.
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Muto
authors.affiliation: The Department of Urology, Hakodate Goryoukaku Hospital.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takahashi
authors.affiliation: The Department of Urology, Hakodate Goryoukaku Hospital.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Takagi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy; D012008:Recurrence; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen